Jayeshkumar Patel, MD
Nephrology · Jersey City, NJNPI 1962509265
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,436 of the $14,122 with a category attached, or 88.1%. It is spread thinly across 31 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,750 and has fallen 75.7% since, to $912 in 2025. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 344 payments — averaging $41.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Novo Nordisk$1K
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$1K
- Amgen$1K
- plus $4K from 25 others
What the payments were for
- Consulting fees$1,2008%
- Travel & lodging$3793%
- Food & beverage$12,43688%
- Education$1071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 59 | $2,634 |
| AstraZeneca | 47 | $1,867 |
| Novo Nordisk | 21 | $1,381 |
| Biohaven Pharmaceuticals, Inc. | 2 | $1,325 |
| AbbVie(2 entities) | 73 | $1,319 |
| Amgen(2 entities) | 31 | $1,239 |
| Boehringer Ingelheim | 13 | $1,045 |
| Abbott | 12 | $884 |
| Phathom Pharmaceuticals, Inc. | 3 | $374 |
| Vifor Pharma, Inc. | 24 | $336 |
| Bayer | 6 | $317 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $178 |
| Cardiovascular Systems Inc. | 1 | $171 |
| Dexcom, Inc. | 4 | $154 |
| Corcept Therapeutics | 1 | $146 |
| Lilly USA, LLC | 8 | $128 |
| Mannkind Corporation | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 6 | $105 |
| Amarin Pharma, Inc. | 1 | $95 |
| Nabriva Therapeutics, PLC | 3 | $52 |
| Nestle Healthcare Nutrition Inc. | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Pfizer | 2 | $29 |
| Merck | 2 | $27 |
| Angiodynamics, Inc. | 1 | $23 |
| Exact Sciences | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,122 in reported general payments places this provider in the 95th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 438 | $397,818 |
| EliquisApixaban | 699 | $313,653 |
| JanuviaSitagliptin Phosphate | 414 | $267,185 |
| JardianceEmpagliflozin | 243 | $224,638 |
| OzempicSemaglutide | 104 | $158,752 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 31 | $128,993 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $122,465 |
| LokelmaSodium Zirconium Cyclosilicate | 132 | $114,583 |
| RybelsusSemaglutide | 57 | $85,085 |
| LinzessLinaclotide | 84 | $75,481 |
| TradjentaLinagliptin | 102 | $68,346 |
| CreonLipase/Protease/Amylase | 26 | $63,764 |
| EntrestoSacubitril/Valsartan | 70 | $61,982 |
| VascepaIcosapent Ethyl | 133 | $58,485 |
| Diclofenac Sodium | 902 | $51,218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma, Breztri Aerosphere, Brilinta | $1,867 | $596,955665 claims |
| PfizerEliquis | $29 | $313,653699 claims |
| MerckJanuvia, Janumet | $27 | $299,746464 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,045 | $292,983345 claims |
| Novo NordiskOzempic, Rybelsus | $1,381 | $243,838161 claims |
| AbbVieLinzess, Creon, Restasis, Vraylar, Lumigan | $1,319 | $222,144208 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $2,634 | $141,054152 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $178 | $48,09334 claims |
| Smith+NephewSantyl | $15 | $42,32332 claims |
| BayerKerendia | $317 | $29,26525 claims |
| AmgenProlia | $1,239 | $22,28413 claims |
| Lilly USA, LLCTrulicity | $128 | $19,84816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Jersey City
- Danny HaddadJersey City$14K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
- Arif AsifNeptune$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.